2 Minute Read
In the current pharma landscape, more than 80% of manufacturers still rely on manual processes to accrue, forecast, and report their gross-to-net (GTN) deductions. This is primarily because of...
3 Minute Read
Explore the best practice recommendations regarding compliance for SPTR.
5 Minute Read
Updates on MDRP NOTICE Release No. 117, Inflation Reduction Act, and Operationalizing Medicare Inflationary Rebates.
9 Minute Read
We asked three market access leaders with significant launch experience across varying therapeutic categories about their launch journey–from pre-launch strategy and planning to post-launch optimization.
4 Minute Read
Whether manufacturers are entering new therapeutic categories, exploring new indications for a current product, or looking to acquire a new product through acquisition, managing Gross-To-Net can be complex.
5 Minute Read
Updates on two significant regulatory topics, including the FDA decision on orphan-drug exclusivity regulations and highlights from the Kaiser Family Foundation 2022 Employer Benefits Survey.
5 Minute Read
We asked three market access leaders with significant launch experience across varying therapeutic categories about their launch journey–from pre-launch strategy and planning to post-launch optimization.
6 Minute Read
Updates on four significant regulatory topics, including the inflation reduction act impact on research and development, Office of Inspector General studies on Average Sales Price, and a shift of...
3 Minute Read
Insights into specialty lite challenges and a new channel strategy that has emerged to help manufacturers balance patient access with their gross-to-net.